NCT06362369 2026-04-13A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy7 Hills Pharma, LLCPhase 1/2 Recruiting126 enrolled
NCT03602079 2023-08-03Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 GeneKlus Pharma Inc.Phase 1/2 Completed49 enrolled
NCT03989115 2023-06-26Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCRevolution Medicines, Inc.Phase 1/2 Completed113 enrolled 22 charts
NCT00333502 2020-05-28Study of CRLX101 (NLG207) in the Treatment of Advanced Solid TumorsLumos PharmaPhase 1/2 Completed62 enrolled